Trial Search Results
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
This study hopes to establish the effects, good or bad, of injecting liver tumors with Pexa-Vec before treating with sorafenib compared to sorafenib treatment alone. Pexa-Vec, an investigational recombinant vaccinia virus, is expected to preferentially replicate in and kill tumor cells. Study investigators will look atPexa-Vec's effects on survival, cancer progression, response rate, quality of life, and safety in patients with hepatocellular carcinoma.
Stanford is currently not accepting patients for this trial.
Lead Sponsor:
SillaJen, Inc.
Stanford Investigator(s):
Intervention(s):
- Biological: Pexastimogene Devacirepvec (Pexa Vec)
- Drug: Sorafenib
Phase:
Phase 3
Eligibility
Inclusion Criteria:
- Histological/cytological diagnosis of primary HCC
- Advanced stage HCC (Barcelona Clinic Liver Cancer [BCLC] Stage C or B per American
Association for the Study of Liver Disease [AASLD] guidelines)
- At least one measurable viable tumor in the liver, ≥1 cm longest diameter (LD), using
a dynamic imaging technique (arterial phase of triphasic computerized tomography [CT]
scan, or dynamic contrast-enhanced magnetic resonance imaging [MRI]), and injectable
under imaging-guidance (CT and/or ultrasound)
- Child-Pugh Class A
- Performance status 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale
- Adequate hematological, hepatic, and renal function:
- Additional inclusion criteria exist
Exclusion Criteria:
- Histological diagnosis of cholangiocarcinoma, hepatocholangiocarcinoma, fibrolamellar
carcinoma and hepatoblastoma
- Symptomatic cardiovascular disease, including but not limited to significant coronary
artery disease (e.g., requiring angioplasty or stenting) or congestive heart failure
within the preceding 12 months
- Current or past history of cardiovascular disease (e.g.. past history of myocardial
infarction, ischemic cardiomyopathy) unless cardiology consultation and clearance has
been obtained for study participation
- History of moderate or severe ascites, bleeding esophageal varices, hepatic
encephalopathy or pleural effusions related to liver insufficiency within 6 months of
screening
- Bulky disease patients - tumors encompassing >50% of the liver volume and / or
inferior vena cava invasion
- Known significant immunodeficiency due to underlying illness (e.g., HIV/AIDS) and/or
immune-suppressive medication including high-dose corticosteroids
- Ongoing severe inflammatory skin condition (as determined by the Investigator)
requiring medical treatment
- History of severe eczema (as determined by the Investigator) requiring medical
treatment
- Additional exclusion criteria exist
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Shawn Niknam
650-721-4080
Not Recruiting